Elevated blood sugar is associated with colorectal cancer in postmenopausal women

Summary: women in the highest third of blood glucose levels were almost twice as likely to develop colorectal cancer over the course of the study.

More evidence that high blood sugar contributes to cancer is presented in a study just published in the British Journal of Cancer that examines the link between elevated fasting glucose and colorectal cancer in postmenopausal women. The authors state:

“It is unclear whether circulating insulin or glucose levels are associated with increased risk of colorectal cancer. Few prospective studies have examined this question, and only one study had repeated measurements.”

So they examined baseline fasting serum insulin and glucose values for 4902 non-diabetic women over 12 years, during which 81 cases of colorectal cancer turned up. The data showed a significant trend:

Baseline glucose levels were positively associated with colorectal cancer and colon cancer risk: multivariable-adjusted hazard ratio (HR) comparing the highest (greater than or equal to 99.5 mg dl−1) with the lowest tertile (<89.5 mg dl−1): 1.74 and 2.25, respectively. Serum insulin and homeostasis model assessment were not associated with risk.”

In other words, glucose in the highest third almost doubles the risk. In this non-diabetic group an association with fasting insulin levels was not observed. However, I can say through extensive experience over 2-3 years having patients suffer through an extended glucose + insulin tolerance test that insulin can be often elevated later in the test but not in the fasting sample. The authors conclude:

These data suggest that elevated serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.”

Curcumin—a better COX-2 inhibitor for colorectal cancer prevention

COX-2 inhibitors, a form of non-steroidal antiinflammatory drug (NSAID) that targets the COX-2 enzyme,  have been recognized for their ability to prevent the growth of colon tumors. They have, however, also been proven to seriously increase the risk for heart attacks and strokes. The authors of paper published recently in the journal Current Colorectal Cancer Reports despite the early hopes for these medications:

“”Nonsteroidal anti-inflammatory drugs are one of the more studied groups of drugs in colorectal cancer chemoprevention because both epidemiological and experimental studies have shown that these drugs reduce the risk of developing colonic tumors. Cyclooxygenase-2 (COX-2), an isoform of cyclooxygenase, plays an important role in colorectal carcinogenesis…However, recent long-term studies have shown that these agents and probably some NSAIDs have an increased risk of cardiovascular events, which has changed the whole scenario.”

In another paper published in the subsequent issue of the same journal, the authors state:

“Recent studies of coxibs indicate that these agents are effective in reducing sporadic adenoma recurrence, but chronic use can result in serious cardiovascular toxicity. These data underscore the need for chemopreventive agents with acceptable risk-to-benefit ratios.”

Happily, a study published in the Annals of the New York Academy of Sciences offers evidence that curcumin, the benign natural phenol extracted from the spice turmeric, also offers a way to inhibit the COX-2 enzyme for colorectal cancer chemoprevention.

“…the AMPK cascade has emerged as an important pathway implicated in cancer control. In this study we investigated the effects of curcumin on apoptosis and the regulatory effect of the AMPK–cyclooxygenase-2 (COX-2) pathway in curcumin-induced apoptosis. Curcumin has shown promise as a chemopreventive agent because of its in vivo regression of various animal-model colon cancers. This study focused on exploiting curcumin to apply antitumorigenic effects through modulation of the AMPK–COX-2 cascade.”

Did curcumin show enough activity in this regard to be meaningful?

Curcumin exhibited a potent apoptotic effect on HT-29 colon cancer cells at concentrations of 50 μmol/L and above. These apoptotic effects were correlated with the decrease in pAkt and COX-2, as well as the increase in p-AMPK.”

They further demonstrated that blocking the effect of curcumin resulted in an increase in COX-2 expression resulting in a replacement of apoptosis (cancer cell death)with proliferation. The authors add in conclusion:

“These results indicate that AMPK is crucial in apoptosis induced by curcumin and further that the pAkt–AMPK–COX-2 cascade or AMPK–pAkt–COX-2 pathway is important in cell proliferation and apoptosis in colon cancer cells.”

Sesamin, a cancer chemopreventative

Molecular Cancer ResearchAs the authors of this paper published last month in Molecular Cancer Research state:

“Agents that are safe, affordable, and efficacious are urgently needed for the prevention of chronic diseases such as cancer.”

They establish their rationale for investigating the sesame seed lignan called sesamin as a cancer chemopreventative:

“Sesamin…has been linked with prevention of hyperlipidemia, hypertension, and carcinogenesis through an unknown mechanism. Because the transcription factor NF-κB has been associated with inflammation, carcinogenesis, tumor cell survival, proliferation, invasion, and angiogenesis of cancer, we postulated that sesamin might mediate its effect through the modulation of the NF-κB pathway.”

They found in fact that sesamin packs quite a punch:

“…sesamin inhibited the proliferation of a wide variety of tumor cells including leukemia, multiple myeloma, and cancers of the colon, prostate, breast, pancreas, and lung. Sesamin also potentiated tumor necrosis factor-α–induced apoptosis and this correlated with the suppression of gene products linked to cell survival, proliferation, inflammation (e.g., cyclooxygenase-2), invasion (e.g., matrix metalloproteinase-9, intercellular adhesion molecule 1), and angiogenesis (e.g., vascular endothelial growth factor). Sesamin downregulated constitutive and inducible NF-κB activation induced by various inflammatory stimuli and carcinogens…”

Those of you who may be pursuing immunopheresis for cancer (filtering TNF-α soluble receptors that barricade tumors from the immune system’s attack) may very well wish to include sesamin in your protocol since it enhances cytotoxic TNF-α activity. Interestingly, sesamin is included in some of our omega-3 fatty acid formulae for brain support as an evidence-based agent for reducing brain inflammation. So the authors’ conclusion is a welcome one:

“Overall, our results showed that sesamin may have potential against cancer and other chronic diseases through the suppression of a pathway linked to the NF-κB signaling.”

Lower Vitamin D brings higher colorectal cancer risk

BMJ 011610The large group of researchers who completed this study published recently in the British Journal of Medicine set out “To examine the association between pre-diagnostic circulating vitamin D concentration, dietary intake of vitamin D and calcium, and the risk of colorectal cancer in European populations.” There were no less than 520,000 participating subjects from 10 countries. The results were clear-cut: “25-(OH)D concentration showed a strong inverse linear dose-response association with risk of colorectal cancer.” [25-(OH)D is the active form of vitamin D that we measure with blood tests.] Interestingly, however, they also found that “Dietary vitamin D was not associated with disease risk.” What does this mean? It highlights a very important point: it is not possible to judge whether you have enough vitamin D in your system by what you consume. There are marked differences in genetic and conditional need, and the only way to reliably know that you are adequate or optimal for vitamin D is by the blood test. The authors concluded: “The results of this large observational study indicate a strong inverse association between levels of pre-diagnostic 25-(OH)D concentration and risk of colorectal cancer in western European populations.” The ‘take home’ message is that colon cancer is another in the long list of conditions for which vitamin D is important prevention—but you have to test to know where you stand.

Pomegranate juice suppresses inflammation of colon cancer

“Phytochemicals from fruits such as the pomegranate may inhibit cancer cell proliferation and apoptosis through the modulation of cellular transcription factors and signaling proteins.” This is from a study that supports the use of pomegranate in the prevention and treatment of colon cancer. The authors conclude: “Therefore, the polyphenolic phytochemicals in the pomegranate can play an important role in the modulation of inflammatory cell signaling in colon cancer cells.”

Cancer & Type 2 Diabetes

In this cohort study of 9577 people followed over eleven years, “significantly increased risks were observed for pancreatic, liver and colon cancer” in patients with type 2 diabetes.  This is one among numerous studies demonstrating the links between insulin as a proliferating hormone, type 2 diabetes and a variety of malignancies.